About us
NanoSanguis, a subsidiary of NanoGroup, is a pioneering biotechnology company dedicated to addressing the organ transplant crisis. Established by a team scientists from Warsaw University of Technology, our company unites advanced scientific expertise with innovative thinking to develop next-generation organ preservation solutions. By leveraging cutting-edge technologies, we aim to push the boundaries in organ transplantation and provide hope to patients worldwide.
Kidney transplantation
Kidney transplantation is the most common type of organ transplant and the only available therapy for patients with end-stage renal disease. Despite over 100.000 kidney transplants performed annually worldwide, the demand by far exceeds supply, leaving hundreds of thousands patients on waiting lists and millions unable to join. As a result patients are left to undergo often lifelong dialysis, which dramatically impacts their health and life quality. The main problem lies in ineffective current organ preservation technologies.
NanOX system
We have developed an innovative solution aimed at expanding donor pool by utilizing kidneys from donors after longer circulatory death (DCD). NanOX is a comprehensive kidney perfusion system that includes a perfusion fluid, a device, and a perfusion kit. Our system offers prolonged organ preservation, additional oxygenation, and simulates physiological processes while operates in sub- and normothermic environment. With this technology we strive to solve the shortage and increase organ availability.
Technology
Organ transplantation faces persistent challenges in preserving organs. Many kidneys are discarded due to ischemia damage or their inability to meet transplant criteria. We are pioneering a nanoparticle-based fluid and device aiming at disruptive change of current standard.
NanOX system represents a groundbreaking synthetic approach to organ preservation, offering an advanced alternative to traditional methods. Designed to function in controlled sub- and normothermic conditions, the system closely simulates the body’s natural processes, creating optimal state for organ maintenance and regeneration.
Read more...
The core of NanOX technology lies in perfluorocarbon nanoformulation. Synthetic nanoparticles mimic red blood cells, transporting oxygen and removing carbon dioxide in almost same way the human blood does. This unique capability sustains metabolism and even regenerates organs, increasing kidney acceptance rate for transplantation. The nanoparticles are scalable and easy to produce.
Perfusion system created by our team has several unique features:
-
Advanced oxygen delivery: NanOX nanoparticles carry more oxygen per volume than human blood and maintain a controlled environment that minimize cellular stress and enhance organ viability,
-
Extended ischemia tolerance: NanOX technology allows for the qualification of organs after prolonged warm ischemia (30-40 min) compared to just a few minutes in conventional systems ,
-
Regeneration capability: NanOX Recovery Box operates in controlled sub- and normothermic oxygen-enriched environment, which stimulates cellular recovery, enabling organ regeneration and better transplant outcomes,
-
Scalability and ease of production: synthetic nanoparticles used in our perfusion solution, NanOX 4 Kidney, are easy to produce in large quantities under sterile conditions.
NanOX is not just about improving numbers; it’s about saving lives and enhancing quality of life for patients worldwide. With its revolutionary approach to organ preservation, NanOX sets a new benchmark for innovation in medical science.
Our team
OUR MANAGEMENT TEAM HAS ALL THE NECESSARY COMPETENCES TO SUCCEED
President of the Management Board
PRZEMYSŁAW MAZUREK
Member of the Management Board
PIOTR MIERZEJEWSKI
Supervisory Board
JERZY GARLICKI
ROBERT DZIUBŁOWSKI
STEFAN BOGUSŁAWSKI
What we do?
Why?
Effects
Partners
OUR PROJECTS ENGAGE KEY OPINION LEADERS IN THE AREA OF TRANSPLANTOLOGY IN POLAND
OUR STUDIES ARE CONDUCTED IN SPECIALIZED RESEARCH INSTITUTIONS
SOME OF OUR SUPPORTERS
GRANT FOR EUROGRANTS
Project financed by the Polish Agency for Enterprise Development under the Smart Growth Operational Programme 2014-2020.
EuroNanoMed III
Project “Nanoporous-Membranes for Intrathecal (Pseudo)Delivery of Drugs (INTREPIDUS)” co-financed by the National Centre for Research and Development under the EuroNanoMed III Joint Transnational Call for Proposal (2020) for „European Innovative Research & Technological Development Projects in Nanmedicine”
EuroNanoMed III
Project “Nanosystems conjugated with antibody fragments for treating brain infections (TARBRAINFECT)” co-financed by the National Centre for Research and Development under the EuroNanoMed III Joint Transnational Call for Proposal (2018) for „European Innovative Research & Technological Development Projects in Nanmedicine”
GRANTS FOR INNOVATION
Project co-financed by the European Regional Development Fund under the Operational Programme Innovative Economy.
SMART GROWTH OPERATIONAL PROGRAMME 2014-2020
Project “OrganFarm- system for long-term ex vivo organ storage” co-financed by the National Centre for Research and Development under the Smart Growth Operational Programme 2014-2020.
MAZOVIAN REGIONAL OPERATIONAL PROGRAM FOR THE YEARS 2014-2020
Project “„Red Blood Cells Substitute” co-financed by the the European Regional Development Fund under the Mazovian Regional Operational Program for the years 2014-2020.
NanoSanguis S.A. | Rakowiecka 36 | 02-532 Warszawa | Polska
NIP: 7010537389 | Sąd Rejonowy dla m.st. Warszawy XIII Wydział Gospodarczy KRS 595165 | Kapitał zakładowy 3 888 560,00 zł w całości wpłacony
Contact
info
[at our domain of]
nanosanguis.com
Rakowiecka 36
02-532 Warsaw, Poland
NanoSanguis S.A.
NIP: 7010537389
REGON: 363505173
Share capital fully paid up of PLN 3 888 560,00